Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 11, 2023
Topotecan, GLP, Carcinoma, Abstract, Rituximab, LSD1, AACR, Cancer prevention, Follicular lymphoma, DLBCL, European Hematology Association, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Biotechnology, Clinical trial, Lenalidomide, NHL, CD20, American Association for Cancer Research, Cyclophosphamide, Salinicola salarius, SCLC, Bortezomib, Congress, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Patient, Toxicology, Neoplasm, Ewing sarcoma, Research institute, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, News, Food, Cancer Prevention and Research Institute of Texas, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Video game

HOUSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022.
  • The decline reflects lower spending on seclidemstat in the 2023 quarter and one-time expenses of $2.0 million related to the purchase of the targeted protein degrader program in the 2022 quarter.
  • “In addition, Salarius continued to execute on plan during the first quarter of 2023 and recent weeks as we advanced the development of SP-3164, our targeted protein degrader.
  • Salarius will be participating in the 2023 BIO International Convention in Boston June 5-8, and the European Hematology Association 2023 Congress in Frankfurt, Germany June 8-11.

TripleBlind Announces Collaboration with Two University of Texas Health-Related Institutions to Advance Public Health Cancer Prevention

Retrieved on: 
Wednesday, March 29, 2023
University of Texas Southwestern Medical Center, MLS, WHNP-BC, University, Moses Austin, Cancer prevention, University of Texas System, University of Texas Health Science Center at San Antonio, Principal investigator, Cancer Prevention and Research Institute of Texas, University of Texas at Austin, Division, DRS, Research, Privacy, Electronic health record, APRN, Doctor of Philosophy, Hepatitis C, Hospital, Patient, HIPAA, Internal medicine, Diagnosis, Research institute, Health, MPH, Death, HCC, Infection, Software, Pharmaceutical industry, Medical device, FIDSA, MD

KANSAS CITY, Mo., March 29, 2023 (GLOBE NEWSWIRE) -- TripleBlind , the leader in automated, real-time data de-identification, today announced an agreement with The University of Texas Southwestern Medical Center and The University of Texas Health Science Center at San Antonio.

Key Points: 
  • KANSAS CITY, Mo., March 29, 2023 (GLOBE NEWSWIRE) -- TripleBlind , the leader in automated, real-time data de-identification, today announced an agreement with The University of Texas Southwestern Medical Center and The University of Texas Health Science Center at San Antonio.
  • With the help of TripleBlind's technology, the agreement aims to empower researchers to study the impact collaborative research has on quality of patient care.
  • The Cancer Prevention and Research Institute of Texas (CPRIT) recently announced $90 million in new grant funding for programs to address the need for better cancer prevention across Texas, including public health screening and treatment for Hepatitis C and Hepatitis B vaccination in patients from low-income South Texas communities.
  • Hepatitis C, a condition that is increasing in younger populations, is a cause of hepatocellular carcinoma liver cancer (HCC), which is the third leading cause of death worldwide .

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023
Myelodysplastic syndrome, Abstract, Rituximab, AACR, University, Cell death, ASH, Cancer prevention, Sarcoma, Multiple myeloma, Drug discovery, Clinical trial, Bone marrow, Lenalidomide, NHL, Chronic myelomonocytic leukemia, American Association for Cancer Research, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Research, MD Anderson Cancer Center, Monroe Dunaway Anderson, Salinicola salarius, Azacitidine, Protein, Acquisition, Patent, Patient, Mouse, Research institute, Ewing sarcoma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, Factorization of polynomials, Food, Cancer Prevention and Research Institute of Texas, Cryptocurrency, Video game, Pharmaceutical industry, Rail freight transport, Vaccine

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021.
  • Research and development expenses were $4.7 million in the fourth quarter of 2022, compared with $2.7 million in the fourth quarter of 2021.
  • As of December 31, 2022, Salarius had cash, cash equivalents and restricted cash of $12.1 million, compared with $29.2 million as of December 31, 2021.
  • Current cash and cash equivalents are expected to fund the company’s planned operations into the fourth quarter of 2023.

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Retrieved on: 
Thursday, February 16, 2023
Organization, Effectiveness, Salinicola salarius, FET, Patient, Cancer prevention, Clinical trial, Cancer Prevention and Research Institute of Texas, Food, Research, Cyclophosphamide, Ewing sarcoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research institute, Topotecan, Pharmaceutical industry

(NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT).

Key Points: 
  • (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT).
  • This $1.48 million payment brings Salarius’ cumulative disbursement from CPRIT to approximately $16.0 million.
  • To date, CPRIT has awarded over $3 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.
  • Salarius was awarded a product development research grant in May 2016 for the development of seclidemstat, and the disbursements are based upon Salarius’ achievement of defined goals and objectives.

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Life, CMML, Cancer prevention, Azacitidine, Sarcoma, Clinical trial, Annual report, Effectiveness, Hematological Cancer Research Investment and Education Act, Salinicola salarius, Cancer Prevention and Research Institute of Texas, Food, MDS, FDA, Poster, Safety, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, MD Anderson Cancer Center, SUSAR, Ewing's sarcoma, Drug development, Survival, Research, Society, Research institute, LSD1, Index (publishing), Biology, University, Patient, Pharmaceutical industry, IND

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that investigators in the Department of Leukemia at the University of Texas MD Anderson Cancer Center presented clinical data on seclidemstat in patients with MDS and CMML at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition underway in New Orleans and virtually.

Key Points: 
  • of the Department of Leukemia and is available in the Investors Events and Presentations section of Salarius’ website here .
  • As of October 2022, nine patients were enrolled with a median follow-up time of 3.9 months.
  • Typically, overall survival is four to six months for patients after failing therapy with hypomethylating agents.
  • The Phase 1 dose-escalation portion of this study will evaluate up to six dose levels of seclidemstat.

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Life, Cancer prevention, Sarcoma, Clinical trial, Annual report, Effectiveness, Hematological Cancer Research Investment and Education Act, Cancer Prevention and Research Institute of Texas, Letter, Food, FDA, Poster, Safety, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, Lenalidomide, Deuterium, SUSAR, Drug discovery, Ewing's sarcoma, Drug development, Research, Society, NHL, Research institute, Biology, Patient, MD Anderson Cancer Center, Rituximab, Vaccine, Pharmaceutical industry, Salinicola salarius, IND, DLBCL

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that yesterday Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, presented positive SP-3164 preclinical data at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition underway in New Orleans and virtually.

Key Points: 
  • Avadomide is an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy efficacy in non-Hodgkin’s lymphomas (NHL) and other hematologic malignancies.
  • This, along with the data presented at ASH showing compelling SP-3164 activity in lymphoma models, supports SP-3164’s potential in NHL for the clinical trial planned for 2023.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.
  • Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

Retrieved on: 
Thursday, December 8, 2022
Conference, Cancer prevention, Sarcoma, Hematological Cancer Research Investment and Education Act, Salinicola salarius, Cancer Prevention and Research Institute of Texas, PIN, Food, Webcast, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, International, MD Anderson Cancer Center, Ewing's sarcoma, Society, Research institute, Biology, Lymphatic system, Patient, Pharmaceutical industry

New preclinical data with Salarius’ targeted protein degrader SP-3164 being presented at ASH will also be reviewed, along with previously announced SP-3164 preclinical data that was presented at the 5th Annual Targeted Protein Degradation Conference.

Key Points: 
  • New preclinical data with Salarius’ targeted protein degrader SP-3164 being presented at ASH will also be reviewed, along with previously announced SP-3164 preclinical data that was presented at the 5th Annual Targeted Protein Degradation Conference.
  • Salarius encourages participants to pre-register for the conference call here to receive a dedicated dial-in number and PIN.
  • Participants may register at any time, including up to and after the call start time.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options.

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries

Retrieved on: 
Monday, December 5, 2022
Technology, Health, Radiology, Oncology, Health Technology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, SCC, Recurrence, TSX Venture Exchange, Pharynx, OTC, JAMA, Breast cancer, Medical imaging, Cancer Prevention and Research Institute of Texas, MD, Analysis, Research institute, MRI, Perimeter, Head, Patient, Cancer prevention, Research, DDS, Breast Cancer Awareness Month, Progression-free survival, Professor, FDA, Pathology, FSE, News, University, Radiation, Tissue, Public expenditure, Tax, Optical coherence tomography, SEDAR, Hope, Legislation, Squamous cell carcinoma, Risk, Dentistry, Medicine

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (Perimeter or the Company) announced the publication of a peer-reviewed research article in JAMA OtolaryngologyHead and Neck Surgery.

Key Points: 
  • Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (Perimeter or the Company) announced the publication of a peer-reviewed research article in JAMA OtolaryngologyHead and Neck Surgery.
  • The studys findings validate the further exploration of the use of Perimeters wide-field Optical Coherence Tomography (WF-OCT) technology to visualize margins during head and neck surgeries.
  • Our research findings suggest that wide-field OCT may be a promising adjunct imaging modality for intraoperative visualization in head and neck surgery, especially at deep margins.
  • Jeremy Sobotta, Perimeters Chief Executive Officer commented, This publication further supports the potential use of our flagship Perimeter S-Series OCT medical imaging technology across several tissue types, including head and neck surgery.

Perimeter Medical Imaging AI Announces Follow-On Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System at New Hospital Site

Retrieved on: 
Tuesday, November 15, 2022
Oncology, Health, Medical Devices, Technology, Hospitals, Surgery, Artificial Intelligence, FDA, TSX Venture Exchange, Analysis, Perimeter, OTC, News, Breast Cancer Awareness Month, FSE, Medical imaging, Breast cancer, MRI, Research, Research institute, Tissue, Cancer prevention, Tax, SEDAR, Legislation, Public expenditure, Cancer Prevention and Research Institute of Texas, Health insurance, Risk management

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) announced another commercial placement of its flagship Perimeter S-Series OCT system at a second hospital within one of the largest healthcare networks in North Texas, which is part of a major national healthcare system.

Key Points: 
  • Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) announced another commercial placement of its flagship Perimeter S-Series OCT system at a second hospital within one of the largest healthcare networks in North Texas, which is part of a major national healthcare system.
  • Jeremy Sobotta, Perimeters Chief Executive Officer stated, Approximately six weeks ago, we announced the commercial placement of our Perimeter S-Series OCT system within a national healthcare network.
  • I am pleased to report that we have now completed the second commercial installation at another hospital within this major healthcare system.
  • About Perimeter Medical Imaging AI, Inc.
    Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.

Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

Retrieved on: 
Tuesday, November 8, 2022
Surgery, Medical Devices, Health, Health Technology, Oncology, Investor, Cancer prevention, Breast cancer, News, Cancer Prevention and Research Institute of Texas, Webcast, FDA, Perimeter, Legislation, Company, OTC, Awareness, Forward-looking statement, SEDAR, Research institute, TSX Venture Exchange, Tissue, Breast Cancer Awareness Month, MRI, Public expenditure, FSE, Research, Tax, Analysis, Time, Risk management

The webcast will be archived on the Company's investor relations webpage for at least 90 days.

Key Points: 
  • The webcast will be archived on the Company's investor relations webpage for at least 90 days.
  • A telephonic playback of the conference call will be available for 14 days after the conference call by calling 1-844-512-2921 or 1-412-317-6671 from abroad and referencing conference ID 13734184.
  • About Perimeter Medical Imaging AI, Inc.
    Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.
  • Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist are forward-looking information.